13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001844645
Total reported value
$307.8M
$307.8M
13 檔
71.2%
The Q1 2026 SEC filing reveals that Pivotal bioVenture Partners Investment Advisor LLC held a total portfolio value of $307.8M, covering 13 public equity positions.
Pivotal bioVenture Partners Investment Advisor LLC executed strategic sector rebalancing during Q1 2026, establishing 2 new positions while fully exiting 1 holdings and trimming 3 positions.
In terms of portfolio concentration, the top 5 core holdings (including PCVX, OCS, EVMN) accounted for 71.2% of total reported equity market value during Q1 2026.
Top New Position Initiated
AVTX
市值: $4.4M
Top Position Liquidated / Trimmed
RALLYBIO CORP
前期市值: $1.6M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | Stock-Other | 28.51% | -1.59% | — | |
| 2 | OCS | Oculis Holding AG | Stock-Other | 15.97% | -9.18% | -26.58% | |
| 3 | EVMN | Evommune Inc | Stock-Other | 15.83% | -7.51% | — | |
| 4 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 11.42% | -0.64% | -0.79% | |
| 5 | TRVI | Trevi Therapeutics Inc | Stock-Other | 6.63% | +3.93% | +23.63% | |
| 6 | IMNM | Immunome Inc | Stock-Other | 5.73% | -0.69% | — | |
| 7 | MPLT | Maplight Therapeutics Inc | Stock-Other | 4.44% | +2.68% | — | |
| 8 | ZBIO | Zenas Biopharma Inc | Stock-Other | 4.14% | -0.09% | — | |
| 9 | BIOA | Bioage Labs Inc | Stock-Other | 4.08% | +1.12% | — | |
| 10 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.58% | +1.03% | — | |
| 11 | RLYB | Rallybio CORP | Stock-Other | 0.96% | +0.60% | — | |
| 12 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.65% | +0.06% | — | |
| 13 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.06% | -0.06% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | +4% | — | Unchanged |
| 2 | EVMN | Evommune Inc | +3.1% | — | Unchanged |
| 3 | BIOA | Bioage Labs Inc | +0.7% | — | Unchanged |
| 4 | TRVI | Trevi Therapeutics Inc | +0.6% | +23.63% | Add |
| 5 | MPLT | Maplight Therapeutics Inc | +0.3% | — | Unchanged |
| 6 | BOLT | Bolt Biotherapeutics Inc | -0.1% | -54.98% | Trim |
| 7 | RXRX | Recursion Pharmaceuticals-a | -0.3% | — | Unchanged |
| 8 | IMNM | Immunome Inc | -0.4% | — | Unchanged |
| 9 | OCS | Oculis Holding AG | -1.7% | -26.58% | Trim |
| 10 | ARQT | Arcutis Biotherapeutics Inc | -3.9% | -0.79% | Trim |
| 11 | ZBIO | Zenas Biopharma Inc | -4.2% | — | Unchanged |
| 12 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 13 | RLYB | Rallybio CORP | — | NEW | New buy |
| 14 | ✓ | Rallybio CORP | — | EXIT | Sold out |
According to official SEC Form 13F filings, Pivotal bioVenture Partners Investment Advisor LLC reported a total U.S. public equity portfolio value of $307.8M across 13 disclosed positions in Q1 2026.
During Q1 2026, Pivotal bioVenture Partners Investment Advisor LLC's top holdings by market value included PCVX (28.5%)、OCS (16.0%)、EVMN (15.8%). The largest single position, PCVX, represented 28.5% of total portfolio value.
In Q1 2026, Pivotal bioVenture Partners Investment Advisor LLC made 7 total portfolio adjustments, initiating 2 new buys, adding to 1 positions, trimming 3 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.